title: Is severe rejection an indication for retransplantation?
authors.affiliation: Division of Transplantation, University of Miami School of Medicine, Miami, Florida 33101-5809, USA.
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Berho
authors.forename: D
authors.initials: D
authors.lastname: Weppler
authors.forename: P
authors.initials: P
authors.lastname: Ruiz
authors.forename: A D
authors.initials: AD
authors.lastname: Pinna
authors.forename: F A
authors.initials: FA
authors.lastname: Khan
authors.forename: J R
authors.initials: JR
authors.lastname: Nery
authors.forename: A G
authors.initials: AG
authors.lastname: Tzakis
mesh_terms: D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007422:Intestines / Q000473:pathology / Q000637:transplantation*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D012086:Reoperation; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology* / Q000401:mortality / Q000473:pathology*; D014781:Viscera / Q000637:transplantation
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3